Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider Daniel Rabinowitz sold 787 shares of the company's stock in a transaction on Tuesday, April 23rd. The stock was sold at an average price of $91.38, for a total transaction of $71,916.06. Following the completion of the transaction, the insider now directly owns 205,552 shares of the company's stock, valued at approximately $18,783,341.76. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.
Daniel Rabinowitz also recently made the following trade(s):
- On Thursday, February 29th, Daniel Rabinowitz sold 20,526 shares of Natera stock. The stock was sold at an average price of $89.01, for a total transaction of $1,827,019.26.
- On Tuesday, February 27th, Daniel Rabinowitz sold 35,307 shares of Natera stock. The stock was sold at an average price of $75.09, for a total transaction of $2,651,202.63.
Natera Stock Performance
NASDAQ:NTRA opened at $91.04 on Wednesday. The stock's fifty day moving average is $86.40 and its 200 day moving average is $66.49. Natera, Inc. has a fifty-two week low of $36.90 and a fifty-two week high of $98.82. The firm has a market capitalization of $10.99 billion, a PE ratio of -24.02 and a beta of 1.37. The company has a debt-to-equity ratio of 0.37, a quick ratio of 3.96 and a current ratio of 4.10.
Have You Seen Elon’s New A.I. Device? (Picture Inside)
From InvestorPlace | Ad
A strange new era for mankind is upon us...
And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day.
Elon believes A.I. is advancing so fast...
This strange new device to protect us against that A.I. threat...
Natera (NASDAQ:NTRA - Get Free Report) last released its earnings results on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share for the quarter, topping analysts' consensus estimates of ($0.73) by $0.09. Natera had a negative return on equity of 62.19% and a negative net margin of 40.16%. The business had revenue of $311.11 million for the quarter, compared to analyst estimates of $300.38 million. On average, sell-side analysts anticipate that Natera, Inc. will post -2.35 earnings per share for the current year.
Institutional Trading of Natera
Hedge funds and other institutional investors have recently bought and sold shares of the business. RiverPark Advisors LLC purchased a new stake in Natera in the fourth quarter worth $27,000. Principal Securities Inc. purchased a new stake in Natera in the fourth quarter worth $32,000. Harvest Fund Management Co. Ltd purchased a new stake in Natera in the third quarter worth $44,000. Oliver Lagore Vanvalin Investment Group increased its stake in Natera by 109.3% in the fourth quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company's stock worth $47,000 after purchasing an additional 389 shares during the period. Finally, Arcadia Investment Management Corp MI increased its stake in Natera by 47.8% in the first quarter. Arcadia Investment Management Corp MI now owns 538 shares of the medical research company's stock worth $49,000 after purchasing an additional 174 shares during the period. Hedge funds and other institutional investors own 99.90% of the company's stock.
Wall Street Analysts Forecast Growth
Several brokerages have commented on NTRA. Craig Hallum began coverage on shares of Natera in a research note on Monday, April 8th. They issued a "buy" rating and a $117.00 price target on the stock. StockNews.com cut shares of Natera from a "hold" rating to a "sell" rating in a research note on Tuesday. The Goldman Sachs Group boosted their price target on shares of Natera from $90.00 to $100.00 and gave the stock a "buy" rating in a research note on Monday, April 15th. Sanford C. Bernstein upgraded shares of Natera from a "market perform" rating to an "outperform" rating and set a $120.00 target price on the stock in a research report on Friday, April 5th. Finally, Piper Sandler lifted their price target on Natera from $70.00 to $110.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 6th. One research analyst has rated the stock with a sell rating and fourteen have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $86.40.
Read Our Latest Research Report on Natera
About Natera
(
Get Free Report)
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
